June

Organix Inc. (June 17, 2021)

AMPAC Fine Chemicals Virginia, LLC (June 17, 2021)

Johnny C. Benjamin, Jr., M.D.; Decision and Order (June 17, 2021)

Tareq A. Khedir Al-Tiae, M.D.; Decision and Order (June 17, 2021)

Xcelience (June 17, 2021)

Andersonbrecon Inc. DBA PCI of Illinois (June 17, 2021)

Final Rule: Placement of N-Ethylpentylone in Schedule I (June 14, 2021)

Usona Institute (June 14, 2021)

Fisher Clinical Services, Inc. (June 14, 2021)

Adiramedica, LLC (June 11, 2021)

Maridose, LLC (June 10, 2021)

Cambrex Charles City (June 10, 2021)

Fisher Clinical Services, Inc. (June 10, 2021)

National Center for Natural Products Research (June 10, 2021)

Final Rule: Placement of Oliceridine in Schedule II (June 10, 2021)

Final Rule: Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA, and 5F-CUMYL-P7AICA in Schedule I (June 10, 2021)

Jennifer L. St. Croix, M.D.; Order Denying Motion To Stay (June 8, 2021)

Designation of 3,4-MDP-2-P Methyl Glycidate (PMK Glycidate), 3,4-MDP-2-P Methyl Glycidic Acid (PMK Glycidic Acid), and Alpha-Phenylacetoacetamide (APAA) as List I Chemicals; Correction (June 7, 2021)

Final Rule: Placement of Remimazolam in Schedule IV (June 2, 2021)

---

May

Purisys, LLC (May 26, 2021)

Almac Clinical Services Incorp. (ACSI) (May 26, 2021)

American Radiolabeled Chem (May 25, 2021)

SpecGX, LLC (May 25, 2021)

Final Rule: Placement of Lasmiditan in Schedule V (May 24, 2021)

SPECGX LLC (May 18, 2021)

Experic LLC (May 18, 2021)

Lipomed (May 18, 2021)

Unither Manufacturing LLC (May 18, 2021)

Patheon API Manufacturing, Inc. (May 12, 2021)

Rosa A. Fuentes, M.D.; Decision and Order (May 11, 2021)

Final Rule: Designation of 3,4-MDP-2-P methyl glycidate (PMK glycidate), 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid), and alpha-phenylacetoacetamide (APAA) as List I Chemicals (May 10, 2021)

Interim Final Rule: Placement of Serdexmethylphenidate in Schedule IV (May 7, 2021)

Indian Flower LLC (May 7, 2021)

Green Rush Organic Farms Inc. (May 7, 2021)

Melanie Baker, N.P.; Decision and Order (May 5, 2021)

Michele L. Martinho, M.D.; Decision and Order (May 5, 2021)

Emmanuel A. Ayodele, M.D.; Decision and Order (May 5, 2021)

Final Rule: Placement of Four Specific Fentanyl-Related Substances in Schedule I (May 4, 2021)

Cargill, Incorporated (May 4, 2021)

VHG Labs DBA LGC Standards (May 4, 2021)

Wildlife Laboratories, LLC (May 4, 2021)

---

April

Final Rule: Placement of 10 Specific Fentanyl-Related Substances in Schedule I (April 27, 2021)

60-Day Notice: New Proposed Collection Exempt Chemical Preparations Application (April 26, 2021)

Rhodes Technologies (April 26, 2021)

Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (April 23, 2021)

Rhodes Technologies (April 23, 2021)

Cardinal Health (April 23, 2021)

Lipomed (April 23, 2021)

Research Triangle Institute (April 21, 2021)

Mark A. Wimbley, M.D.; Decision and Order (PDF) (April 21, 2021)

Michael Jones, M.D.; Decision and Order (April 21, 2021)

Javaid A. Perwaiz, M.D.; Decision and Order (April 21, 2021)

Research Triangle Institute (April 21, 2021)

Scottsdale Research Institute (April 21, 2021)

The Pharmacy Place; Order (PDF) (April 21, 2021)

Final Rule: Removal of Samidorphan From Control (April 19, 2021)

Jennifer L. St. Croix, M.D.; Decision and Order (PDF) (April 12, 2021)

Royal Emerald Pharmaceuticals (April 5, 2021)

Brenton D. Goodman, M.D.; Decision and Order (April 2, 2021)

Kendrick E. Duldulao, M.D.; Decision and Order (April 2, 2021)

ThinkPur, LLC (April 1, 2021)

Sharp Clinical Services, Inc. (April 1, 2021)

---

March

Final Rule: Placement of cyclopentyl fentanyl, isobutyryl fentanyl, para-chloroisobutyryl fentanyl, para-methoxybutyryl fentanyl, and valeryl fentanyl in Schedule I; Correction (March 31, 2021)

Extension of Temporary Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-144 in Schedule I of the Controlled Substances Act (March 31, 2021)

Ester Mark, M.D.; Decision and Order (PDF) (March 31, 2021)

Eric R. Shibley, M.D.; Decision and Order (March 31, 2021)

Roozbeh Badii, M.D.; Decision and Order (March 31, 2021)

Proposed Rule: Designation of Methyl alpha-phenylacetoacetate, a Precursor Chemical Used in the Illicit Manufacture of Phenylacetone, Methamphetamine, and Amphetamine, as a List I Chemical (March 30, 2021)

Proposed Rule: Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-144 in Schedule I (March 30, 2021)

MMJ 95, LLC (March 26, 2021)

Shertech Laboratories, LLC (March 24, 2021)

Medi-Physics Inc. dba GE Healthcare (March 24, 2021)

Perkinelmer, Inc. (March 24, 2021)

Lawrence E. Stewart; Decision and Order (March 22, 2021)

Proposed Rule: Placement of Four Specific Fentanyl-Related Substances in Schedule I (March 18, 2021)

Noramco Coventry, LLC (March 18, 2021)

Cambridge Isotope Lab; Correction (March 16, 2021)

Purisys, LLC (March 16, 2021)

Patheon Pharmaceuticals Inc. (March 9, 2021)

Stepan Company (March 9, 2021)

Groff NA Hemplex LLC (March 9, 2021)

Proposed Rule: Placement of 10 Specific Fentanyl-Related Substances in Schedule I (March 3, 2021)

Final Rule: Placement of Lemborexant in Schedule IV (March 3, 2021)

Stepan Company (March 2, 2021)

Temporary Placement of Brorphine in Schedule I (March 1, 2021)

Cosmic Light LLC (March 1, 2021)

Groff NA Hemplex, LLC (March 1, 2021)

Microgenics Corporation Thermo Fisher Scientific (March 1, 2021)

---

February

Proposed Rule; Reopening of Comment Period: Suspicious Orders of Controlled Substances (February 25, 2021)

Chattem Chemicals (February 25, 2021)

S&B Pharma, Inc. (February 25, 2021)

Myonex Inc. (February 25, 2021)

AJC Industries, Inc. (February 24, 2021)

GGGYI LLC (February 24, 2021)

Sigma Aldrich Research Biochemicals, Inc. (February 24, 2021)

Livwell Michigan, LLC (February 24, 2021)

Synthcon LLC (February 24, 2021)

Globyz Pharma, LLC (February 24, 2021)

30-Day Notice: Registration for CSA Data-Use Request (February 22, 2021)

Patheon API Manufacturing, Inc. (February 19, 2021)

Milad I. Shaker, M.D.; Decision and Order (February 19, 2021)

Michael W. Carlton, M.D.; Decision and Order (PDF) (February 19, 2021)

Ibrahim Al-Qawaqneh, D.D.S.; Decision and Order (February 19, 2021)

VHG Labs DBA LGC Standards (February 19, 2021)

North Star Holdings California, LLC (February 16, 2021)

Mountain Trading LLC (February 16, 2021)

JW Colorado, LLC (February 16, 2021)

Titan Health LLC (February 16, 2021)

PCI Synthesis (February 16, 2021)

S and B Pharma, Inc. (February 16, 2021)

Noramco Coventry, LLC (February 16, 2021)

Sigma Aldrich Co., LLC (February 16, 2021)

Siegfried USA, LLC (February 16, 2021)

Sterling Pharma USA, LLC (February 5, 2021)

Noramco, Inc. (February 5, 2021)

Mylan Pharmaceuticals Inc. (February 4, 2021)

---

January 2021

Indigenous Peyote Conservation Initiative (January 28, 2021)

Siemens Healthcare Diagnostics Inc. (January 14, 2021)

IsoSciences, LLC (January 14, 2021)

Cedarburg Pharmaceuticals (January 12, 2021)

Organix, Inc. (January 12, 2021)

Siegfried USA, LLC (January 12, 2021)

Natural Fulfillment LLC (January 12, 2021)

Medi-Physics, Inc. dba GE Healthcare (January 12, 2021)

S&B Pharma LLC dba Norac Pharma (January 12, 2021)

Proposed Rule: Amending Regulations To Require Online Submission of Applications for and Renewals of DEA Registration (PDF) (January 7, 2021)